SYNRG

Across TCGA pan-cancer cohorts, SYNRG mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SYNRG data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SYNRG mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SYNRG expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SYNRG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.575	0.320	.001	43	view →
CCRCC	DFS	Tertile	II,III,IV	0.972	0.064	.006	33	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	30	view →
COAD	DFS	Tertile	All	1.000	0.918	.043	18	view →
LSCC	OS	Tertile	All	1.000	0.917	.037	6	view →
UCEC	DFS	Median	II,III,IV	0.880	0.545	.046	4	view →
GBM	DFS	Median	All	0.834	0.660	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SYNRG–PDAC (DFS)

Open the PDAC breakdown →